The team expect it to be rolled out next year after trials showed up to 80% protection against the deadly disease.
Crucially, say the scientists, their vaccine is cheap and they already have a deal to manufacture more than 100 million doses a year. BBC News
See also:
- Efficacy and immunogenicity of R21/Matrix-M vaccine against clinical malaria after 2 years' follow-up in children in Burkina Faso: a phase 1/2b randomised controlled trial (open access) The Lancet Infectious Diseases
No comments:
Post a Comment